Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Structure Posts Positive Obesity Drug Results; Raises $476 Million

publication date: Jun 7, 2024

Structure Therapeutics, a San Francisco-Shanghai clinical stage company, had a busy week, announcing positive clinical results for its obesity drug and then raising $476 million via an offering of its ADSs. Structure is an AI/Structure-based company that develops small molecule versions of biologic and peptides drugs. It was co-founded in 2021 by Schrödinger, an AI company based in New York that became a strategic partner of the company previously known an ShouTi. Structure's stock price jumped from $32 per ADS before the trial news and now sits at $54 per ADS, a 65% increase. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital